Prodrugs of scutellarin: Ethyl, benzyl and N,N-diethylglycolamide ester synthesis, physicochemical properties, intestinal metabolism and oral bioavailability in the rats

European Journal of Pharmaceutical Sciences

Volumn 29, Issue 5, 2006, Pages 385-393

  Cao, Feng ^a   Guo, Jian Xin ^a   Ping, Qi Neng ^a   Liao, Zheng Gen ^b  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b JIANGXI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Bioavailability; Emulsion; Glycolamide ester; Intestinal metabolism; Oral absorption; Prodrugs; Scutellarin

Indexed keywords

4',5,6 TRIHYDROFLAVONE 7 GLUCORONIDE; BENZYL 4',5,6 TRIHYDROXYFLAVONE 7 GLUCURONIDE ESTER; BUFFER; CYCLODEXTRIN; ESTER DERIVATIVE; FLAVONOID; N,N DIETHYL 2 CHLOROACETAMIDE ESTER; N,N DIETHYLGLYCOLAMIDE 4',5,6 TRIHYDROXYFLAVONE 7 GLUCURONIDE ESTER; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG DEGRADATION; DRUG HYDROLYSIS; DRUG METABOLISM; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; HUMAN; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; NONHUMAN; PARTITION COEFFICIENT; PH MEASUREMENT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT;

ANIMALS; APIGENIN; BIOLOGICAL AVAILABILITY; CYCLODEXTRINS; FLAVONES; GASTROINTESTINAL CONTENTS; GLUCURONIC ACIDS; GLUCURONIDES; INTESTINES; MALE; MOLECULAR STRUCTURE; PRODRUGS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33750729593     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.07.007     Document Type: Article

References (33)

1. Annaert P., Tukker J.J., Gelder J.V., Naesens L., Clercq E.D., Kinget R., and Augustijns P. In vitro, ex vivo, and in situ intestinal absorption characteristics of the antiviral ester prodrug adefovir dipivoxil. J. Pharm. Sci. 89 8 (2000) 1054-1062
2. Augustijns P., Annaert P., Heylen P., Van den Mooter G., and Kinget R. Drug absorption studies of prodrug esters using the Caco-2 model: evaluation of ester hydrolysis and transepithelial transport. Int. J. Pharm. 166 (1998) 45-53
3. Beaumont K., Webster R., Gardner I., and Dack K. Design of ester prodrugs to enhance oral absorption of poorly permeable compounds: challenges to the discovery scientist. Curr. Drug Metab. 4 (2003) 461-485
4. Benita S., and Levy M.Y. Submicron emulsions as colloidal drug carriers for intravenous administration: comprehensive physicochemical characterization. J. Pharm. Sci. 82 (1993) 1069-1079
5. Bundgaard H. Novel chemical approaches in prodrug design. Drugs Fut. 16 5 (1991) 443-458
6. Bundgaard H., and Nielsen N.M. Glycolamide esters as a novel biolabile prodrug type for non-steroidal anti-inflammatory carboxylic acid drugs. Int. J. Pharm. 43 (1988) 101-110
7. Cao F., Guo J.X., and Ping Q.N. The physicochemical characteristics of freeze-dried scutellarin-cyclodextrin tetracomponent complexes. Drug Dev. Ind. Pharm. 31 (2005) 747-756
8. Chen J., Lin H.M., and Hu M. Metabolism of flavonoids via enteric recycling: role of intestinal disposition. J. Pharmcol. Exp. Ther. 304 (2003) 1228-1235
9. Chen X.X., and He B. Effects of breviscapine on the changes in antioxidant enzyme activity induced by cerebral ischemia reperfusion in rats. J. Chi. Pharm. Sci. 7 (1998) 91-93
10. Cook C.S., Karabatsos P.J., Schoenhard G.L., and Karim A. Species dependent esterase activities for hydrolysis of anti-HIV prodrug glycovir and bioavailability of active sc-48334. Pharm. Res. 12 8 (1995) 1158-1164
11. Crauste-Manciet S., Brossard D., Decroix M.O., Farinotti R., and Chaumeil J.C. Cefpodoxime-proxetil protection from intestinal lumen hydrolysis by oil-in water submicron emulsions. Int. J. Pharm. 165 (1998) 97-106
12. Crauste-Manciet S., Huneau J.F., Decroix M.O., and Chaumeil J.C. Cefpodoxime proxetil esterase activity in rabbit small intestine: a role in the partial cefpodoxime absorption. Int. J. Pharm. 149 (1997) 241-249
13. Dias C.S., Anand B.S., and Mitra A.K. Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J. Pharm. Sci. 91 3 (2001) 660-668
14. Gelder J.V., Shafiee M., Clercq E.D., Penninckx F., Mooter G.V., Kinget R., and Augustijns P. Species-dependent and site-specific intestinal metabolism of ester prodrugs. Int. J. Pharm. 205 (2000) 93-100
15. Ge Q.H., Zhou Z., Zhi X.J., Ma L.L., and Chen X.H. Pharmacokinetics and absolute bioavailability of breviscapine in beagle dogs. Chi. J. Pharm. 34 12 (2003) 618-620
16. Hirayama F., Ogata T., and Yano H. Release characteristics of a short-chain fatty acid, n-butyric acid, from its β-cyclodextrin ester conjugate in rat biological media. J. Pharm. Sci. 89 11 (2000) 1487-1494
17. Krise J.P., Charman W.N., Charman S.A., and Stella V.J. A novel prodrug approach for tertiary amines. Part 3. In vivo evaluation of two N-phosphonooxymethyl prodrugs in rats and dogs. J. Pharm. Sci. 88 9 (1999) 928-932
18. Leisen C., Langguth P., Herbert B., Dressler C., Koggel A., and Spahn-Langguth H. Lipophilicities of baclofen ester prodrugs correlate with affinities to the ATP-dependent efflux pump P-glycoprotein: relevance for their permeation across the blood-brain barrier?. Pharm. Res. 20 5 (2003) 772-778
19. Lesser S., Cermark R., and Wolffram S. Bioavailability of quercetin in pigs is influenced by the dietary fat content. J. Nutr. 134 (2004) 1508-1511
20. Liu H., Yang X.L., Wang Y., Tang X.Q., Jiang D.Y., and Xu H.B. Protective effects of scutellarin on superoxide-induced oxidative stress in rat cortical synaptosomes. Acta Pharmacol. Sin. 24 (2003) 1113-1117
21. Liu Y., and Hu M. Absorption and metabolism of flavonoids in the CACO-2 cell culture model and a perused rat intestinal model. Drug Metab. Dispos. 30 4 (2002) 370-377
22. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193 (1951) 265-275
23. Minagawa T., Kohno Y., Suwa T., and Tsuji A. Species differences in hydrolysis of isocarbacyclin methyl ester (tei-9090) by blood esterases. Biochem. Pharmacol. 49 10 (1995) 1361-1365
24. Mizen L., and Burton G. The use of esters as prodrugs for oral delivery of beta-lactam antibiotics. Pharm. Biotech. 11 (1998) 11345-11365
25. Nicolaos G., Crauste-Manciet S., Farinotti R., and Brossard D. Improvement of cefpodoxime proxetil oral absorption in rats by oil-in water submicron emulsion. Int. J. Pharm. 263 (2003) 165-171
26. Niemi R., Turhanen P., Vepsalainen J., Taipale H., and Jarvinen T. Bisphosphonate prodrugs: synthesis and in vitro evaluation of alkyl and acylmethoxy esters of etidronic acid as bioreversible prodrugs of etidronate. Eur. J. Pharm. Sci. 11 (2000) 173-180
27. Prueksaritanont T., Gorham L.M., Hochman J.H., Tran L.O., and Vyas K.P. Comparative studies of drug-metabolizing enzymes in dog, monkey, and human small intestines, and in Caco-2 cells. Drug Metab. Dispos. 24 6 (1996) 634-642
28. Sugawara M., Huang W., Fei Y.J., Leibach F.H., Ganapathy V., and Ganapathy M.E. Transport of valganciclovir, a ganciclovirprodrug, via peptide transporters PEPT1 and PEPT2. J. Pharm. Sci. 89 (2000) 781-789
29. Tammara V.K., Narurkar M.M., Crider A.M., and Khan M.A. Synthesis and evaluation of morpholinoalkyl ester prodrugs of indomethacin and naproxen. Pharm. Res. 10 8 (1993) 1191-1199
30. Ungell A.L., Bergstrand S.B., Sjoberg A., and Lennernas H. Membrane transport of drugs in different regions of the intestinal tract of the rat. J. Pharm. Sci. 87 (1998) 360-366
31. Wang Y.X. A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab. Dispos. 27 8 (1999) 855-859
32. Yano H., Hirayama F., Kamada M., Arima H., and Uekama K. Colon-specific delivery of prednisolone-appended a-cyclodextrin conjugate: alleviation of systemic side effect after oral administration. J. Control. Release 79 (2002) 103-112
33. Yoshigae Y., Imai T.I., Aso T., and Otagiri M. Species differences in the disposition of propranolol prodrugs derived from hydrolase activity in intestinal mucosa. Life Sci. 62 14 (1998) 1231-1241